Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups. We evaluated whether imatinib (340 mg/m(2)/d) with an intensive chemotherapy regimen improved outcome in children ag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2009-11, Vol.27 (31), p.5175-5181
Hauptverfasser:	SCHULTZ, Kirk R, BOWMAN, W. Paul, RUTLEDGE, Robert, BURDEN, Laura, JORSTAD, Dean, CARROLL, Andrew, HEEREMA, Nyla A, WINICK, Naomi, BOROWITZ, Michael J, HUNGER, Stephen P, CARROLL, William L, CAMITTA, Bruce, ALEDO, Alexander, SLAYTON, William B, SATHER, Harland, DEVIDAS, Meenakshi, CHENGUANG WANG, DAVIES, Stella M, GAYNON, Paul S, TRIGG, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Benzamides Biological and medical sciences Bone Marrow Transplantation Child Child, Preschool Disease-Free Survival Female Hematologic and hematopoietic diseases Humans Imatinib Mesylate Infant Kaplan-Meier Estimate Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Original Reports Philadelphia Chromosome Piperazines - administration & dosage Piperazines - adverse effects Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Pyrimidines - administration & dosage Pyrimidines - adverse effects Risk Factors Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!